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ABSTRACT 
We previously demonstrated PAR2 starts upstreamed with tissue factor (TF) and factor 
VII (FVII), inhibited autophagy via mTOR signaling in HCC.  However, the mechanism 
underlying for merging functions of PAR2 with the coagulation system in HCC 
progression remained unclear. The present study aimed to investigate the role of TF, FVII 
and PAR2 in tumor progression of HCC.  
The expressions of TF, FVII and PAR2 from HCC specimens were evaluated by 
immunohistochemical stains and Western blotting. We found that the expression of FVII, 
but not TF and PAR2, directly related to the vascular invasion and the clinical staging. 
Importantly, a lower level of FVII expression was significantly associated with the longer 
disease-free survival. The addition of FVII but not TF induced the expression of PAR2 
and phosphorylation of ERK1/2, whereas knockdown of FVII decreased PAR2 
expression and ERK1/2 phosphorylation in HCC cell lines. Furthermore, levels of 
phosphor-TSC2 (Ser664) were increased after treatment by FVII and PAR2 agonist 
whereas these were significantly abolished in the presence of a potent and specific 
MEK/ERK inhibitor U0126. Moreover, mTOR knockdown highly reduced Hep3B 
migration which could be reverted by FVII but not TF and PAR2. These results indicated 
that FVII/PAR2 signaling through MEK/ERK and TSC2 axis for mTOR activation has 
potent effects on the migration of HCC cells. In addition, FVII/PAR2 signaling elicits an 
mTOR-independent signaling which promotes hepatoma cell migration in consistent with 
the clinical observations.  
Our study indicates that levels of FVII, but not TF, are associated with tumor migration 
and invasiveness in HCC and provides clues that evaluation of FVII expression in HCC 
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may be useful as a prognostic indicator in patients with HCC and may form an alternative 
target for further therapy. 
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INTRODUCTION 
 
Hepatocellular carcinoma (HCC) is the seventh most common malignancy worldwide 1. 
The current options for the treatment of this cancer consist of surgical resection, liver 
transplantation, percutaneous locoregional ablation therapy, and chemotherapy including 
molecular targeted therapy 2, 3. However, the high recurrence rate is still a major concern 
after any treatment, although the underlying mechanisms are still not fully defined 4. A 
better understanding of these mechanisms may lead to novel therapeutic approaches. 
Recent advances have highlighted that protease-activated receptor-2 (PAR2) has a 
regulatory function in HCC cell invasion 5. Therefore, a crucial role for a PAR2-mediated 
signaling pathway in HCC progression can be hypothesized. 
  
Coagulation factor VII (FVII) participates in the initiation of the extrinsic pathway by 
binding to tissue factor (TF) 6. Formation of TF-FVIIa complex leads to activation of 
coagulation cascade and platelet activation 7. In addition, increasing evidence indicates 
that the TF/FVII complex is also involved in physiological and pathophysiological 
processes involved in the development and spread of cancer, including angiogenesis, 
tumor migration and invasion, and cell survival 8, 9, 10. On tumor cells, TF/FVII-dependent 
signaling primarily activates PAR2, which belongs to a family of four G-protein-coupled 
receptors 11, and thereby shapes the tumor microenvironment by inducing an array of pro-
angiogenic and immune modulating cytokines, chemokines and growth factors 12. Several 
studies have documented that increased expression of TF mediated by TF-FVII-PAR2 
signaling correlates with aggressive phenotypes in colorectal, breast, pancreatic cancers 
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and gliomas 13, 14. Hence, targeting the pathway may be an effective approach for cancer 
therapy. However, the role of TF-FVII-PAR2 signaling in HCC has not been well 
investigated. 
 
Herein, we present evidence that FVII-PAR2 signaling but not TF plays an important role 
in HCC cell migration and invasion mediated through the p44/42 mitogen-activated 
protein kinase (MAPK) pathway. Of importance, our study indicates that FVII plays a 
critical role in HCC tumor biology regulating TF-FVII-PAR2 signaling. 
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MATERIALS AND METHODS 
 
Patients and tissue samples 
From Aug 2009 to Aug 2010, 100 patients who underwent curative hepatic resection for 
HCC at the Chang Gung Memorial Hospital, were recruited into this study. The diagnosis 
of HCC was based on the criteria of practice guidelines 2, 15. All patients were followed in 
the outpatient clinic with regular surveillance for the recurrence by serum ɑ-fetoprotein 
level and ultrasound every 3 months and/or contrast-enhanced computerized tomography 
scan if recurrent tumor was suspected. All patients were followed up until death or June 
2012. The demographics, clinical character, pathological findings of HCC, recurrence 
and survival were recorded. The clinicopathologic characteristics of 100 HCC patients 
are summarized in Table 1. The study protocol was approved by the ethic committee of 
Chang Gung Memorial Hospital. Written informed consent was obtained from each 
patient. Tumor and adjacent tumor-free specimens (control tissues) were obtained 
immediately after surgical resection. The investigators who performed the laboratory 
studies of TF, FVIIa, and PAR2 expression were blinded to the clinicopathologic data. 
 
Immunohistochemistry (IHC) staining  
The paraffin-embedded tissue blocks were sectioned for IHC. The slides were incubated 
overnight at 4°C in humidified chambers with primary rabbit polyclonal anti-TF (Santa 
Cruz, Santa Cruz, CA), PAR2 (Santa Cruz), FVII (Abcam, Cambridge, UK ), and CD34 
(Santa Cruz) antibody. Antigen–antibody complexes were detected by the avidin– biotin–
peroxidase method, using diaminobenzidine as a chromogenic substrate (DAKO, 
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Carpinteria, CA). Finally, the slides were counterstained with haematoxylin and then 
examined under light microscopy. 
 
Western blot analysis 
Total protein were homogenized with loading buffer, separated by 10% SDS-PAGE and 
transferred to nitrocellulose membranes. The membranes were probed with primary 
antibodies at 4°C overnight and then were incubated for 1 hour with respective 
conjugated secondary antibodies (1:2000, Cell Signaling Technology, Billerica, MA, 
USA). Immunoreactive proteins were visualized by ECL western blot detection reagents 
(Millipore), and quantitated using a G:BOX iChemi XL imaging systems (J&H 
Technology Co. Ltd.). The western blot reactivity of TF, FVII, and PAR2 were classified 
as high if staining in the tumor was higher than the non-tumor part of the biopsy. 
 Immunofluorescence studies of human HCC tissue 
Cells were fixed in 4% paraformaldehyde and incubated with primary antibody at 4°C 
overnight and Texas Red or FITC-conjugated secondary antibody for 2 h at room 
temperature. Extensive washing with PBS was performed between each step and before 
mounting and examination by fluorescence microscopy (Olympus). 
 
Evaluation of microvessel density (MVD) 
MVD was determined by the presence of CD34 as descried by Weidner et al. 16. Briefly, 
tumor and non-tumor tissue sections were scanned at low power fields (x 40) to find the 
areas that showed the most intense neovascularization (hot spots). Individual 
microvessels were counted in five fields at high power (x 200). Any positively stained 
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endothelial cell or endothelial-cell cluster that was clearly separated from adjacent 
microvessels, tumor cells, and connective elements was considered to be a single and 
countable microvessel. Vessel lumens were not necessary for a structure to be defined a 
vessel lumen. The final MVD was the mean value obtained from the counts of five fields, 
which was expressed as the absolute number of microvessels/ high-power field (HPF).  
 
Cells and culture condition 
Human hepatoma cell lines, Hep3B, HepG2 and PLC, and breast cancer cell lines, MDA-
MB-231 and MCF7, obtained from American Type Culture Collection (Manassas, VA, 
USA), were cultivated in an incubator under a 5% carbon dioxide atmosphere at 37 °C in 
a relative humidity of 95% and were maintained in DMEM (Invitrogen, Karlsruhe, 
Germany) with 10% FBS (Invitrogen), 100 U/ml penicillin (Invitrogen), 100 mg/ml 
streptomycin (Invitrogen) and 4 mM L-glutamine (Invitrogen). Recombinant human TF 
and FVII were purchased from R&D Systems (Minneapolis, MN, USA). PAR1 agonist 
peptide TFLLR-NH2 and PAR2 agonist peptide SLIGKV-NH2 were purchased from 
Peptides International (Louisville, KY, USA).The working concentration of recombinant 
proteins and agonist peptides were 200 ng/ml. 
 
Tumor xenograft mouse model 
Severe combined immunodeficiency (SCID) mice (4 weeks old) were housed under 
standard conditions and cared for according the institutional guidelines for animal care. 
For the xenograft tumor growth assay, HepG2 cells (5 x 106) were injected 
subcutaneously into the right dorsal flank. Treatment, which was initiated when the tumor 
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reached 5mm in diameter, was through directly subcutaneous injection of either FVIIa, 
TF, or PAR2 (2 µg/ml) agonist every other day. After 30 days, the mice were euthanized 
and the tumors were excised and extract protein for western blot analysis  
. The mice experiments were performed in accordance with U.S. National Institutes of 
Health guidelines, and the Chang Gung Institutional Animal Care and Use Committee 
Guide for Care and Use of Laboratory Animals. This study was conducted under the 
approval of Chang Gung Institutionally Animal Care and Use Committee (IACUC 
Approval NO 2011092001). 
 
siRNA Transient Transfection 
The siRNA for knocking down target gene expression was obtained from Santa Cruz. In 
brief, cells were cultured in 6-well plates and transfected with 30 nM target gene-specific 
siRNA or control siRNA using GenMute siRNA transfection reagent (signaGen 
Laboratories, MD, city state) and harvested for further analysis 48 hrs after transfection. 
 
Invasion assay 
A polycarbonate filter (8µm pore size) precoated with Matrigel (Becton Dickinson, 
Franklin Lakes, NJ) was used. Briefly, cells were resuspended in serum-free DMEM and 
seeded in 6μm PET Transparent plates (Millipore, Billerica, MA). Prior to addition of the 
suspended cells, the Matrigel chambers were rehydrated at 37 °C in a humidified tissue 
culture incubator with DMEM. 10% FCS was used as an invasion stimulus and added to 
the wells of the companion plate. After 24 h, invaded cells were fixed in 100% methanol 
for 2 min and subsequently stained in 0.1% Cristal Violet (Sigma-Aldrich) in ddH2O for 
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2 min. Invaded cells were counted under a light microscope counting 10 high power 
fields per chamber. 
 
Migration assay  
Cells were seeded and grown to confluence in DMEM medium. A scratch was made 
using a Ibidi culture insert and another medium change was performed. Wells were 
photographed using an inverted light microscope (Nikon, Dusseldorf, Germany) and 
cultivated for 24 h. After incubation the wells were photographed again. A grid system 
was used and the same coordinates were used for the photographs before and after 
incubation to compare the same spots. For quantitative analysis, the first and second 
photographs were correlated and the number of cells migrated into the scratch were 
counted. 
 
Statistical analysis 
Continuous data were presented as median and range and compared between groups 
using the Mann-Whitney U test. Categorical variables were compared using the chi-
square test (or Fisher’s exact test where appropriate). Correlations between continuous 
variables were determined using the Spearman rank correlation test. Survival rates were 
calculated using the Kaplan-Meier method, and the difference in survival was compared 
with the log-rank test. Receiver operating characteristic (ROC) curves were generated to 
capture the best trade-off between sensitivity and specificity of age, AFP level, and tumor 
size for correlation with TF, FVII, and PAR2. Statistical analysis was performed with the 
SPSS software package for Windows (SPSS 15.0 for Windows; SPSS Inc., Chicago, IL, 
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USA). All P values were derived from 2-tailed tests and a level of <0.05 was accepted as 
statistically significantly. 
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RESULTS 
Correlation of TF, FVIIa, and PAR2 with clinicopathologic characteristics of 100 
HCC patients 
The expression of TF, FVII, and PAR2 were examined by western blot analysis in 100 
pairs of HCC patients (representative pairs shown in Figure 1A and 1B). Compared with 
the paired non-tumor tissues, high levels (defined as greater than a 1-fold increase) of 
both FVII and PAR2 expression in 83 of 100 HCC cases. In contrast, the expression of 
TF was greater in only 37% of HCC specimens. Furthermore, an association analysis 
showed that no significant difference between FVII and PAR2 expression among these 
100 HCC specimens (P = 0.845). We further examined the correlation between the 
expression of TF, FVII, and PAR2 and clinicopathologic parameters (Table 2). The 
results indicated that TNM stage ( P ＜  0.001), tumor capsule  (P = 0.029), and 
microvenous invasion (P = 0.003) were significantly correlated with FVII expression. 
But the size and number of tumors were not associated with FVII expression. On the 
other hand, microvenous invasion (P = 0.059) was almost significantly correlated with 
PAR2 expression. The findings suggested that FVII and PAR2 may be involved in HCC 
progression. 
 
Correlation between FVII and microvascular density (MVD) 
To further investigate the correlations between FVII, TF, and PAR2 and tumor 
characteristics, the levels of FVII, TF, and PAR2 were compared by IHC (Figure 1C). 
Consistently, compared with the non-tumor tissues, a profound increase in expression of 
FVII and PAR2 was detected in HCC tissue (85% and 80% of samples respectively). 
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Likewise, increased expression of TF was detected in 33.3% samples. To estimate the 
correlation between MVD and expression of FVII and PAR2, specific staining of 
capillary-like vessels by anti-CD34 was examined (Figure 1D). The MVD was 
significantly higher in tumors with high level FVII than those with low level of FVII 
(median, 46 vs. 81 /HPF, P = 0.001, Figure 1E) 
 
FVII levels predict disease-free survival in HCC patients after curative resection 
All 100 HCC patients undergoing hepatectomy were followed-up at regular intervals 
until death or until the time of this writing, and the median duration of follow-up was 18 
months (range, 1 to 27 months). The tumors in these patients were categorized as high (n 
= 83) or low (n = 17) expressers of FVII according to the results of the western blots. 
Patients with high FVII levels had a significantly shorter disease-free survival than those 
with low FVII levels (P = 0.026, Figure 1F). However, there was no correlation between 
tissue TF and PAR2 levels and disease-free survival rates (data not shown).  
 
FVII regulates p-ERK1/2 via PAR2 in vitro   
We primarily examined 4 HCC cell lines (Hep3B, HepG2, Huh, and PLC) and 2 breast 
cancer cell lines as positive control (MDA-MB-231 and MCF7) 17, 18 to assess whether 
these cells endogenously express TF, FVII, and PAR2. As expected, western blot analysis 
showed that HCC cell lines can express TF, FVII, and PAR2 proteins (Supplementary 
Figure 1). To determine how TF/FVII/PAR2 signaling is working in HCC cells, activated 
FVII (FVIIa, 200 ng/ml) were added to the cultures of Hep3B cell line, and the 
expression of PAR2 was qualitatively observed on immunofluorescence (IF) microscopy. 
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The levels of PAR2 and phosphorylated-ERK1/2 (p-ERK1/2) were quantitatively 
determined by western blot analysis. As shown in Figure 2, FVIIa increased the 
expression of PAR2 as detected qualitatively by IF staining which shown marked 
expression of PAR2 in cell membrane after FVIIa treatment. The dose-dependent 
increase of PAR2 and p-ERK1/2 were observed in both Hep3B and HepG2 cell lines by 
western blot (Figure 3A and 3B), whereas knockdown of FVII by siRNA demonstrated 
notable reduction in the levels of PAR2 and p-ERK1/2 (Figure 3C). However, TF 
treatment (200 ng/ml) did not alter PAR2 and p-ERK1/2 levels (Figure 3D). Furthermore, 
FVIIa also exhibited a time-dependent up-regulation in levels of PAR2 and p-ERK1/2 in 
Hep3B cells (Figure 3E).  
 
FVII/PAR2 signaling regulates TSC2/mTOR phosphorylation via ERK 
The mammalian target of rapamycin (mTOR) is frequently dysregulated in various 
cancer cells and abnormally activated in a proportion of HCC patients 19, which is under 
investigation as a potential target to suppress liver tumor growth and metastasis 20, 21. We 
have previously demonstrated that TF/FVII/PAR2 signaling negatively regulates 
autophagy via mTOR activation which promotes proliferation of Hep3B cells in vitro 22. 
To investigate the potential role of ERK1/2 in mTOR activation by this coagulation 
signaling, we first examined the effect of a specific MEK/ERK inhibitor U0126 in 
FVII/PAR2-mediated mTOR activation. 
Western blot analysis demonstrated that levels of the phosphorylated ERK1/2 (p-ERK), 
mTOR (p-mTOR, Ser2448, active form) as well as the downstream substrate 4EBP1 (p-
4EBP1, Ser65/Thr70) which activated by FVII/PAR2 signaling were suppressed by U0126 
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treatment in a dose-dependent manner (Figure 4). In addition, levels of the 
phosphorylated TSC2 (p-Ser664) induced by FVII/PAR2 signaling were also reverted by 
U0126 treatment indicated that mTOR activation by FVII/PAR2 activities relies upon 
ERK-mediated TSC2 phosphorylation.  
 
Knockdown of FVII and PAR22 inhibits cell invasion and migration via MEK/ERK 
and TSC2/mTOR pathway 
We further investigated the role of TF/FVII/PAR2 signaling in tumor cell invasion and 
migration. As shown in Figure 6, the invasion of Hep3B cells were significantly 
suppressed by knockdown of FVII and PAR2 genes, however no significant effect of TF 
knockdown on Hep3B cell invasion was observed (Figure 5A). In the scratch-migration-
assay, knockdown of TF, FVII and PAR2 significantly reduced migration of Hep3B cells 
(Figure 5B). Furthermore, migration of Hep3B cells was significantly attenuated by 
mTOR knockdown (Figure 5C). Similar results were also observed in the invasion assay 
of Hep3B cells (data not shown). The results indicated that the signal through 
FVII/PAR2/mTOR axis via ERK activity was involved in HCC cell migration and 
invasion. Moreover, Hep3B cells reveal reduced migration activity upon knockdown of 
mTOR was significantly restored by treatment of FVIIa and PAR2 agonist (Figure 5D). 
This result suggested that FVII/PAR2 signaling might promote HCC cell migration 
through both mTOR-dependent and -independent pathways.  
 
FVII increased expression of p-ERK1/2 and MVD in a xenograft mouse model 
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In a mouse xenograft tumor model, normal saline (Control), FVIIa, TF and PAR2 agonist 
were injected into growing subcutaneous tumors every other day for 30 days. Although 
the number and size of tumors were similar (data not shown), injection of FVIIa, but not 
TF, increased the expression of PAR2 and levels of p-ERK1/2 in tumor cells, analyzed by 
both western blot and IHC (Figure 6A and 6B). Importantly, injection of FVIIa also 
increased MVD as evidenced by CD34 staining (Figure 6B).  
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DISCUSSION 
 
Recent studies showed that PAR2 plays an important role in promoting HCC cell 
invasion, through the pathway of p42/p44 MAPKs 5. The upstream stimulators of TF and 
FVII, which form a binary complex, have also been shown to be involved with tumor 
biology in various cancers such as breast, colorectal cancer, as well as glioma 14, 17, 23. 
However, the role of TF and FVII in tumor progression of HCC has until now remained 
elusive.  
It is universally accepted that FVII is manufactured by liver cells and circulates in the 
bloodstream, primarily in a zymogen (inactive) form, i.e. FVII 6. Only approximately one 
percent of total FVII antigen circulates in the activated enzyme (FVIIa) form, which is 
insufficient to initiate coagulation under physiological conditions 24. The presence of 
procoagulant TF increases the conversion of inactive FVII, to the activated two-chain 
form, and this initiates the coagulation serine protease cascade when FVIIa forms a 
binary complex with the extracellular domain of TF. In addition to this central role in 
initiation of coagulation, recent studies have shown that ectopic synthesis of FVII by 
cancer cells activates cancer cell migration and metastasis 18, 25. Recent studies further 
indicated that reduction of TF and FVIIa exerted an inhibitory effect on tumor growth in 
xenograft models of breast and colorectal cancer 26, 27. Our previous study also 
demonstrated that TF/FVII/PAR2 signaling regulates autophagy mainly via mTOR 
signaling and impacts on cell survival of hepatoma cells 22. These findings suggest that 
FVII is indispensable in coagulation-mediated enhancement of tumor growth.  
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In the present study, despite a wide variation in the expression of TF, FVII, and PAR2 by 
HCC tumors and non-tumor tissues, we observed a significant correlation between the 
expression of FVII and PAR2 by tumor specimens and a significant association between 
FVII and the clinical staging. Furthermore, patients with high levels of FVII expression 
in HCCs had a significantly worse disease-free survival than those tumors with low levels 
of FVII expression. Importantly, expression of FVII was exclusively associated with the 
presence of PAR2 but not downstream products of coagulation function such thrombin 
and its signal transduction effecter PAR1 (data not shown). Therefore, the clinical 
observations suggest that FVII plays an important role in tumorigenesis of HCC through 
a PAR2 signaling pathway.  
 
Our in vitro data confirmed that FVII, but not soluble TF, upregulates the p-ERK1/2 
mediated with PAR2. Moreover, the invasion- and migration-associated phenotypes 
could be effectively abolished by silencing FVII expression in HCC cells. Although 
many studies have revealed that TF-FVII-PAR2 signaling can initiate cell signal 
transduction in the pathogenesis of cancers and promotes cell migration and invasion 14, 17, 
23, the detailed signaling transduction mechanisms responsible for the TF-FVII-PAR2 in 
HCC are not fully understood. Here we showed that FVII and PAR2 agonist increase the 
phosphorylation of ERK1/2, however no significant change in ERK phosphorylation was 
observed in TF treatment.  We speculate that TF is expressed in HCC tissue with an 
excess amount, whereas the amount of FVII determines the proportion of TF that is 
engaged with FVII in the binary complex (active form) to regulate HCC tumor 
progression. Our data from the mouse xenogrraft model showed that injection of FVIIa 
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increased vascular density but not the size and number of the tumors. The results are 
consistent with our clinical findings, which demonstrated that the expression of FVII by 
HCC was associated with vascular invasion and capsulations of tumor but not the number 
and size.   
 
Recent studies have documented that the levels of TF expression in primary colorectal, 
breast, and lung cancer correlate with aggressive cancer phenotypes and metastatic 
disease 27, 28, 29, 30, 31. Poon et al. indicated a correlation between TF expression and 
invasiveness in human HCC 32. However, in the present study, there was no correlation 
between TF and the presence of FVII, PAR2, or clinicopathological features. Our results 
are thus more consistent with the findings of Rullier, who has reported no correlation 
between TF and HCC progression 33.  Similarly, other studies indicate that TF is not 
required for tumor growth 34, 35, 36. Taking all together, TF could play an important role in 
tumor progression in many but not all cancers. Although our previous findings have 
shown that TF indeed regulates survival of HCC cells via antagonizing autophagy 
through mTOR signaling, our results indicated that TF will not become a reliable 
prognostic marker at least in part for HCC progression.  
It has been generally accepted that tumor cell motility is necessary for cancer 
dissemination 37. The molecular basis to acquire ability to colonize other organs by 
invading tumor cells has been long studied, but it still remains a largely unmet challenge 
in therapeutic control on metastatic dissemination 38, 39. Especially in China and other 
East Asian countries, survival of HCC patients has improved due to advances in surgical 
techniques such as orthotopic liver transplantation and perioperative nursing care, long-
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term survival after surgical resection remains low owing to risk of recurrence and 
metastasis 40, 41. Thus, to investigate the molecular mechanisms of HCC metastasis, it is 
of great interest to identify impaired metastatic suppressors responsible for the metastatic 
potential.  
In this study, we have shown that knockdown of FVII and PAR2 significantly reduced 
HCC invasion and migration. We also showed that FVII-PAR2 signaling is a contributor 
to tumor migration in HCC which may through both mTOR-dependent and mTOR-
independent pathways. Inhibition of FVII-PAR2 signaling may thus represent an 
effective approach to targeted cancer therapy. Although there is an increased risk of 
bleeding with specific FVIIa inhibitors 26, 42, a recent phase I study indicated that PCI-
27483, a selective inhibitor of FVIIa which promotes a 2.5 to 3.0 fold change in 
prothrombin time in animal studies, is nevertheless well tolerated in advanced pancreatic 
cancer patients 43. Although phase II study of this agent is ongoing, based on our results, 
it might prove to be an agent with therapeutic utility in HCC.  Furthermore, we confirmed 
that metastatic suppressors NME1 and BHLHE41 were highly induced in Hep3B cells 
with FVII and PAR2 knockdown. Indeed, we also found treatment of FVII and PAR2 
agonist significantly decrease expression of NME1 and BHLHE41 (Supplementary 
Figure 2). Moreover, another abundantly expressed member of NME gene family NME2 
was highly increased only in HCC cells with FVII knockdown, but not in cells with 
PAR2 silencing (data not shown). These results indicate that metastatic suppressors could 
play a pivotal role in FVII-associated vascular invasion and poor prognosis in HCC 
patients. However, the details of the underlying mechanism need to be further clarified. 
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Taken together, we suggest that FVII levels in HCC patients may have prognostic 
significance, which may be particularly useful in the management of patients after HCC 
resection. It might be useful to offer adjuvant therapy after HCC resection to those 
patients with high levels of FVII expression, who have a poor disease-free survival rate. 
Further clinical studies are required to verify the prognostic efficacy of FVII levels in a 
large cohort of HCC patients, and the trials for adjuvant treatment after resection is 
approaching. 
In summary, we have presented for the first time that increased FVII expression by tumor 
cells correlates with progression of HCC and acts as a poor prognostic factor after 
surgery and demonstrated that FVII/PAR2 through p-ERK1/2 signaling is involved in 
HCC progression. Importantly, we have presented evidence that FVII plays a novel role 
of the FVII/PAR2 signaling pathway in HCC, and provide mechanistic insights not only 
affecting mTOR but modulating metastatic suppressors into our clinical observations. In 
the future, this work indicates that FVII may be a candidate marker for the development 
of prognostic and therapeutic strategies for HCC malignancy.  
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FIGURE LEGENDS 
 
Figure 1. FVII overexpression correlates with PAR2 in human HCC and disease free 
survival. (A) Western blot analysis of TF, FVII, and PAR2 in 4 representative HCC 
tissues (T) and their paired non-tumor (N) tissues. β-actin was used as a loading control. 
(B) FVII and PAR2 over-expressed (defined as greater than a 1-fold increase) in human 
HCC tumor compared with adjacent non-tumor tissues, and they are positively correlated 
with no significant difference among 100 cases (P = 0.845). (C) The typical profiles of 
IHC staining with anti-TF, FVII or PAR2 antibody illustrated that greater 
immunoreactivity for FVII and PAR2 were found in the tumor region than in the non-
tumor. (D) The endothelial cells of blood vessels were stained by IHC with an anti-CD34 
antibody in one paired HCC and non-tumor tissues. (E) Relationship between FVII 
expression and microvessel count in paired HCC and nontumor tissues. The lines through 
the idle of the boxes represent the median, while the top and bottom of the boxes are the 
25th and 75th percentiles. The error bars represent measurement range, original 
magnification: 200  . (F) Overexpression of FVII (defined as greater than 1-fold 
increase in tumor tissue compared to its paired non-tumor tissue) is associated with the 
recurrence in patients with HCC after curative resection.  
 
Figure 2. The effects of FVIIa on the expression of PAR2 in Hep3B cell line. 
Immunofluorescence was also used to detect the up- and down-regulation of PAR2 in 
Hep3B cells treated with activated FVII (FVIIa) and FVII siRNA, respectively. In cells 
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treated with FVIIa, prominent PAR2 staining was detected in the cell membrane (arrow, 
magnification 200). 
 
Figure 3. FVII, but not TF, increases PAR2 expression and p-ERK1/2 levels in dose-
dependent and time-dependent manners. Quiescent monolayers of Hep3B  (A) and 
HepG2 (B) cells (1 x 105) were treated with a control serum free medium or medium 
supplemented with recombinant FVIIa (NovoSeven® RT) for series of concentrations 
(10, 20, 40, 60, 80, 100, 150, and 200 ng/ml). After 6 hours, cells were harvested and 
detected for TF, FVII, PAR2, p-ERK1/2, and β-actin by western blotting analysis. The 
levels of PAR2 and p-ERK1/2 were gradually increased both in Hep3B and HepG2 cells. 
(C) The levels of PAR2 and p-ERK1/2 were significantly reduced by knockdown of FVII 
using siRNA both in Hep3B and HepG2 cells. (D) Hep3B cells were treated with a 
control serum free medium or medium supplemented with TF (Merck) for series of 
concentrations (10, 20, 40, 60, 80, 100, 150, and 200 ng/ml). After 6 hours, cells were 
harvested and detected for TF, FVII, PAR2, p-ERK1/2, and β-actin by western blotting 
analysis. The levels of PAR2 and p-ERK1/2 were not gradually increased by increasing 
concentration of TF. (E) Hep3B cells were treated with medium supplemented with 
FVIIa for a time-series analysis (0, 1, 3, 6 12 and 24 h). The levels of PAR2, pERK1/2 
but not TF were gradually increased in a time-dependent manner. 
 
Figure 4. The effects of MEK/ERK inhibition by U0126 on the levels of p-ERK, p-
mTOR, p-4EBP1 and p-TSC2-Ser664 in Hep3B cells. Hep3B cells were treated with 
FVIIa (200 ng/ml) in the absence or presence of U0126 (10 or 20 M) 24 h, and total 
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amount of cells were harvested and detected for ERK1/2, p-ERK1/2, mTOR, p-mTOR, 
4EBP1, p-4EBP1, p-TSC2-Ser664, TSC2 and β-actin by western blot assay. All results 
are expressed as the mean ± SD from three independent experiments. The levels of 
pERK1/2, p-mTOR, p-4EBP1 as well as p-TSC2-Ser664 induced by FVIIa were 
significantly abolished by U0126. 
 
Figure 5. Effects of TF/FVII/PAR2 on the tumor phenotype. (A) Invasion: Hep3B cells 
transfected with TF siRNA (30 nM), FVII siRNA (30 nM), or PAR2 siRNA (30 nM) for 
48 h were placed on top of a Matrigel barrier. At the end of a 24-hour incubation period 
at 37°C, the number of cells that migrated across the Matrigel barrier to the underside of 
the membrane was determined. (B) Migration: Hep3B cells transfected with TF siRNA 
(30 nM), FVII siRNA (30 nM), or PAR2 siRNA (30 nM) for 48 h were cultivated to 
optical confluence, and a scratch was performed subsequently on a medium. After 24 h 
incubation at 37°C, cell migration was measured by counting as described in 
experimental procedures. (C) Hep3B cells cultured in 1% serum were pre-transfected 
with mTOR siRNA (30 nM) for 24 hours. Knockdown of mTOR significantly attenuated 
the ability of Hep3B to close the scratch. (D) The attenuated migration of Hep3B cells by 
mTOR knockdown was reverted partly by FVIIa and PAR2 agonist, but not TF treatment. 
Representative results from three independent experiments are shown. 
 
Figure 6. The effect of FVII on PAR2, p-ERK1/2 and CD34 levels in mouse xenograft 
model. Subcutaneously grown HepG2 tumors were injected into NOD/SCID mice. TF, 
FVIIa, or PAR2 agonist was directly injected into the grafted tumors. (A) The expression 
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levels of the 3 coagulation factors and p-ERK1/2 in tumor tissue were determined by 
western blot analyses. (B) Immunohistochemistry for PAR2, p-ERK1/2, and CD34 in 
tumor tissue treated with TF, FVIIa and PAR2 were also determined. Representative 
results from five independent animal experiments are shown. FVII significantly increased 
levels of PAR2, p-ERK1/2 and the microvessel density (MVD) in HepG2 xenograft.  
 
Supplementary Figure 1. Expression of TF, FVIIa and PAR2 are observed in a variety 
of tumor cell lines. Western blot analyses of FVII, TF, and PAR2 expression in 4 HCC 
cell lines (Hep3B, HepG2, Huh7, PLC) and breast cancer cell lines (MCF7, MDA-MB-
231).  
 
Supplementary Figure 2. The effect of FVII/PAR2 signaling on the expression of anti-
metastatic genes. Quantitative real-time PCR analyses of NME1 and BHLHE41 mRNA 
expression in Hep3B cells treated with FVIIa (200 ng/ml) or PAR2 agonist (200 ng/ml), 
and transfected with either FVIIa siRNA (30 nM) or PAR2 siRNA (30 nM) for 24 h were 
performed. GAPDH mRNA expression was used as an internal standard. The data are 
expressed as the fold increase over untreated control (mean ± SD) from three independent 
experiments is shown in the histogram above the blots. *P< 0.05, vs. control group. 
Expression of NME1 and BHLHE41, two metastatic suppressors were significantly 
reduced by FVIIa and PAR2 agonist whereas highly increased by both FVII and PAR2 
knockdown in Hep3B cells.  
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Table 1. Clinicopathological features of 100 patients with HCC undergoing hepatectomy 
Patient Demographics  
Age (years) (median; range) 59 (34－83) 
Sex (M : F) 79 : 21 
AFP (ng/ml) (median; range) 22 (2－342193) 
Tumor size (cm) (median; range)a 3.9 (1.0－19.3) 
Liver cirrhosis (+) (%) 54 (54) 
Hepatitis (B : C : B+C : NBNC) 57 : 22 : 4 : 17 
TNM stage (I : II : III) 24 : 51 : 25 
Pathological features  
Capsule (yes : no) 21 : 77 
Satellite nodule (yes : no) 24 : 76 
Micro vascular invasion (yes : no) 56 : 44 
Histological grade (I : II : III) 9 : 82 : 5 
a Measured by the length of the largest tumor nodule. 
 
 
1 
 
1 
Table 2. Correlation of TF, FVII and PAR2 expression with clinicopathological characteristics 
in 100 patients with HCC 
  FVII  TF  PAR2  
Variable Total T  > 
N 
N > 
T 
P 
valuea 
T  > 
N 
N > 
T 
P 
valuea 
T > 
N 
N > 
T 
P 
valuea 
Age    0.779   0.532   0.709 
≧ 50 years 79 66 13  28 51  65 14  
< 50 years 21 17 4  9 12  18 3  
Sex    0.270   0.257   0.779 
Male 79 68 11  27 52  66 13  
Female 21 15 7  10 11  17 4  
Cirrhosis    0.661   0.993   0.132 
Present 54 44 10  20 34  42 12  
Absent 46 39 7  17 29  41 5  
Hepatitis    0.707   0.454   0.321 
B 57 48 9  21 36  48 9  
C 22 17 5  9 13  18 4  
B+C 4 4 0  0 4  2 2  
NBNC 17 14 3  7 10  15 2  
AFP    0.270   0.619   0.222 
≧ 200 ng/ml 30 23 7  10 20  27 3  
< 200 ng/ml 70 60 10  27 43  56 14  
Tumor size    0.316   0.847   0.940 
≧ 5 cm 42 33 9  16 26  35 7  
 
 
2 
 
2 
< 5 cm 58 50 8  21 37  48 10  
TNM stage    <0.001   0.880   0.187 
I 24 13 11  8 16  17 7  
II 51 50 1  20 31  44 7  
III 25 20 5  9 16  22 3  
Encapsulation    0.029   0.199   0.703 
Present 21 14 7  5 16  17 4  
Absent 77 68 9  30 47  65 12  
Microvenous 
invasion 
   0.003   0.593   0.059 
Present 56 52 4  22 34  50 6  
Absent 44 31 13  15 29  33 11  
Satellite 
nodule 
   0.195   0.304   0.566 
Present 24 22 2  11 13  19 5  
Absent 79 61 15  26 50  64 12  
T: tumor; N: nontumor 
a Categorical data were compared using a chi-square test 
 
